Seikagaku’s Pain Drug Gets Advisory Panel OK, But With Limited Indication

The injection for radicular leg pain appears likely to be approved, but with a very prescriptive label to help balance safety concerns and a lack of long-term outcomes data.

Man sitting on couch wincing in pain, holding his leg.
Patients with radicular leg pain could have a new treatment option following a positive advisory committee recommendation for Seikagku's condoliase. (Shutterstock)

Seikagaku Corporations’s radicular leg pain treatment should be approved as long as the drug label is narrower than currently proposed and includes tight safety controls, a US Food and Drug Administration advisory panel said.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US Advisory Committees

More from Product Reviews

Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval

 

The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.

Semaglutide For MASH Among Raft Of New EU Filings

 

Novo Nordisk’s application seeking EU marketing approval to use its GLP-1 receptor agonist to treat cirrhotic metabolic dysfunction-associated steatohepatitis is one of 15 new drug filings the European Medicines Agency has started reviewing. Meanwhile, Arrowhead’s filing for its familial chylomicronemia syndrome, plozasiran, is being fast tracked.

Brazil’s ANVISA Clarifies Registration Procedures For Biologicals

 

Brazil’s drug regulator has published a new technical note updating guidelines on registration and post-registration procedures for biological products.